The CRAFITY score: A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations

被引：23
|
作者：
Yang, Yi [1 ,2 ,3 ]
Ouyang, Jingzhong [4 ]
Zhou, Yanzhao [4 ]
Zhou, Jinxue [4 ]
Zhao, Hong [1 ,2 ,3 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hepatobiliary Surg, Natl Canc Ctr, Canc Hosp,Natl Clin Res Ctr Canc, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Gene Editing Screening & Res, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dev R&D Digest Syst Tumor Drugs, Beijing, Peoples R China
[4] Zhengzhou Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Canc Hosp, Zhengzhou, Henan, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2022年 / 77卷 / 02期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.jhep.2022.03.018
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：574 / 576
页数：3
相关论文
共 50 条
  • [41] Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Ji, Yuan
    Ge, Ning-Ling
    Qu, Xu-Dong
    Chen, Lingli
    Shi, Wen-Kai
    Li, Mei-Ling
    Zhu, Jin-Jin
    Tan, Chang-Jun
    Tang, Zhao-You
    Zhou, Jian
    Fan, Jia
    Sun, Hui-Chuan
    LIVER CANCER, 2021, 10 (04) : 320 - 329
  • [42] Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD-1 inhibitors? Further validation should be performed
    Yang, Shiye
    Liang, Huoqi
    Li, Xing
    Qian, Jiayi
    Ming, Zhibing
    HEPATOLOGY INTERNATIONAL, 2024, 18 (03) : 1058 - 1059
  • [43] A novel AFP-M2BPGi score has better performance than CRAFITY score in predicting survival for patients with viral hepatocellular carcinoma undergoing immunotherapy
    Lee, Pei-Chang
    Wu, Chijung
    Huang, Kuo-Wei
    Lee, ChiehJu
    Lee, I-Cheng
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    JOURNAL OF HEPATOLOGY, 2023, 78 : S496 - S497
  • [44] The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab
    Lieb, Sabine
    Ebel, Sebastian
    Seehofer, Daniel
    Berg, Thomas
    van Boemmel, Florian
    HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (01) : 148 - 150
  • [45] Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
    Wang, Hong-Kai
    Wan, Fang-Nin
    Gu, Wei-Jie
    Zhu, Yao
    Dai, Bo
    Shi, Guo-Hai
    Zhang, Hai-Liang
    Ye, Ding-Wei
    ONCOTARGET, 2016, 7 (42) : 68943 - 68953
  • [46] Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond
    Huo, Teh-Ia
    Liao, Jia-, I
    Ho, Shu-Yein
    HEPATOLOGY INTERNATIONAL, 2023, 17 (02) : 512 - 513
  • [47] Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment
    Kaneko, Shun
    Tsuchiya, Kaoru
    Yasui, Yutaka
    Tanaka, Yuki
    Inada, Kento
    Ishido, Shun
    Kirino, Sakura
    Yamashita, Koji
    Hayakawa, Yuka
    Nobusawa, Tsubasa
    Matsumoto, Hiroaki
    Kakegawa, Tatsuya
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Tamaki, Nobuharu
    Takahashi, Yuka
    Nakanishi, Hiroyuki
    Irie, Takumi
    Ariizumi, Shun-Ichi
    Kurosaki, Masayuki
    Izumi, Namiki
    JGH OPEN, 2022, 6 (05): : 301 - 308
  • [48] Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma
    Cagnin, Silvia
    Donghia, Rossella
    Martini, Andrea
    Pesole, Pasqua Letizia
    Coletta, Sergio
    Shahini, Endrit
    Boninsegna, Giulia
    Biasiolo, Alessandra
    Pontisso, Patrizia
    Giannelli, Gianluigi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (22)
  • [49] Treatment of hepatocellular carcinoma (HCC) with the tyrosine kinase inhibitor Imatinib.
    Armbrust, T
    Baumhoer, D
    Werner, J
    Schleyer, E
    Ramadori, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 360S - 360S
  • [50] Anti angiogenesis tyrosine kinase inhibitor vandetanib as a radiosensitizer for hepatocellular carcinoma
    Znati, Sami
    CANCER RESEARCH, 2019, 79 (13)
12345